B.S., M.B.A, CEO, Immusoft
Sean Ainsworth is CEO of Immusoft (Seattle, Wash) a highly innovative company developing the Immune System Programming (ISP) technology platform – a B cell immunotherapy designed for sustained in vivo drug delivery of biologic medicines for diseases requiring lifetime treatment with enzymes replacement therapy, monoclonal antibodies, or protein-based drugs. Sean has twenty years of experience in pharmaceuticals and biotechnology. He has had deep involvement in the launch of three earlier startup companies, Compendia Bioscience, Inc., GeneVivo, LLC, and most recently RetroSense Therapeutics, which was acquired by Allergan in 2016 for $60M. Sean holds a BS in Microbiology from University of California, San Diego and an MBA in strategy and finance from Washington University in St. Louis.
Immunotherapy Showcase: B Cells as Biofactories: Autologous, Non-Viral Gene Delivery